Shares of Moderna Inc.
MRNA,
+5.17%
were up 2.3% in premarket trading on Wednesday, the day after the company’s stock price hit an all-time high of $234.60 when the market closed on Tuesday. Moderna has one authorized product, its two-dose, mRNA-based COVID-19 vaccine; the global success of its shot, along with BioNTech
BNTX,
-0.17%
and Pfizer Inc.’s
PFE,
-0.05%
COVID-19 vaccine, has opened the door for broader interest in mRNA technology. Moderna’s stock has soared 124.4% so far this year, while the S&P 500
SPX,
+0.03%
is up 14.2%.
